Related Experiment Video

Updated: Jul 14, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Adjuvant trastuzumab: progress, controversies, and the steps ahead

A A Joy1, J R Mackey

  • 1Department of Oncology, University of Alberta, and the Cross Cancer Institute, Edmonton, Alberta.

Current Oncology (Toronto, Ont.)
|June 20, 2007
PubMed

Insights

Trastuzumab significantly reduces relapses in women with HER2-positive early-stage breast cancer. This targeted therapy is now a standard treatment, improving patient outcomes and offering hope for more effective systemic therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunotherapy

Background:

  • Trastuzumab, a monoclonal antibody targeting the Her-2 oncoprotein, emerged as a significant advancement in breast cancer treatment in 2005.
  • Its efficacy in HER2-positive early-stage breast cancer demonstrated a substantial reduction in disease recurrence.

Purpose of the Study:

  • To summarize key findings from major adjuvant trastuzumab trials.
  • To discuss controversies surrounding its use and suggest improvements in adjuvant systemic therapy.

Main Methods:

  • Review of four major clinical trials evaluating adjuvant trastuzumab therapy.
  • Analysis of outcomes and side effect profiles in patients with HER2-positive breast cancer.

Main Results:

  • Adjuvant trastuzumab demonstrated a significant reduction in relapse rates, preventing approximately half of expected recurrences.
  • The drug has been widely adopted as a standard of care in Canadian healthcare systems.

Conclusions:

  • Trastuzumab represents a major breakthrough in treating HER2-positive early-stage breast cancer.
  • Further research is needed to optimize adjuvant systemic therapy for better tolerability and effectiveness in this patient subgroup.

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...